Literature DB >> 18785286

Halothane hepatitis in Iran: a review of 59 cases.

Payam Eghtesadi-Araghi1, Amirali Sohrabpour, Homayoon Vahedi, Mehdi Saberi-Firoozi.   

Abstract

AIM: To study halothane hepatitis (HH) in Iran and its associated risk factors.
METHODS: We retrospectively studied files of all cases diagnosed with HH referred to three referral hospitals and four private centers in Iran from April 1994 to September 2006. Information on age at surgery, gender, medications history, obesity, history of previous exposure, previous reaction to halothane, familial history, type of surgery, perioperative hypoxia or sepsis, morbidity and mortality were recorded and analyzed.
RESULTS: A total of 59 cases were identified. Forty-eight (81%) were women. The median age at the time of surgery was 44 years (range, 18 to 80 years). Sixty percent of patients were above 40-year-old. Obesity was observed in 22.2%. Previous history of exposures to halothane was noted in 61% of which 50% had history of post-exposure reaction. Coronary artery bypass graft (CABG), cholecystectomy, and cosmetic surgeries (mainly weight reduction) were the most frequent surgeries. The mortality rate was 12.2%. In patients developing encephalopathy, it was as high as 50%.
CONCLUSION: HH remains an important cause of morbidity and mortality in centers still using this anesthetic. However, a large percentage of these cases could have been avoided. To lessen occurrence of further cases of HH, the authors suggest that in female patients having a history of surgery (or delivery) with general anesthesia, the use of halothane should be absolutely avoided. Utilization of proper substitutes in adults' anesthesia is advocated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18785286      PMCID: PMC2744064          DOI: 10.3748/wjg.14.5322

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  48 in total

1.  Predictors of gastrointestinal complications in cardiac surgery.

Authors:  A Zacharias; T A Schwann; G L Parenteau; C J Riordan; S J Durham; M Engoren; N Fenn-Buderer; R H Habib
Journal:  Tex Heart Inst J       Date:  2000

2.  Hyperinsulinemia, dyslipidemia, and obesity as risk factors for hospitalized gallbladder disease. A prospective study.

Authors:  Lori L Boland; Aaron R Folsom; Wayne D Rosamond
Journal:  Ann Epidemiol       Date:  2002-02       Impact factor: 3.797

Review 3.  Halothane hepatitis: a critical review.

Authors:  F M Carney; R A Van Dyke
Journal:  Anesth Analg       Date:  1972 Jan-Feb       Impact factor: 5.108

4.  Hepatic necrosis associated with halothane anesthesia.

Authors:  R L Peters; H A Edmondson; T B Reynolds; J C Meister; T J Curpey
Journal:  Am J Med       Date:  1969-11       Impact factor: 4.965

5.  Halothane-related hepatitis. A clinical study of twenty-six cases.

Authors:  P J Moult; S Sherlock
Journal:  Q J Med       Date:  1975-01

Review 6.  Gallstone disease. Pathogenesis of gallstones: A genetic perspective.

Authors:  Frank Grünhage; Frank Lammert
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

7.  Jaundice after repeated exposure to halothane: an analysis of Reports to the Committee on Safety of Medicines.

Authors:  W H Inman; W W Mushin
Journal:  Br Med J       Date:  1974-01-05

8.  Determinants of gastrointestinal complications in cardiac surgery.

Authors:  Giuseppe D'Ancona; Richard Baillot; Brigitte Poirier; Francois Dagenais; José Ignacio Saez de Ibarra; Richard Bauset; Patrick Mathieu; Daniel Doyle
Journal:  Tex Heart Inst J       Date:  2003

9.  Summary of the national Halothane Study. Possible association between halothane anesthesia and postoperative hepatic necrosis.

Authors: 
Journal:  JAMA       Date:  1966-09-05       Impact factor: 56.272

10.  [Halothane-induced hepatitis. 8 case reports].

Authors:  Riadh Daghfous; Sihem el Aïdli; Mohamed Sfaxi; M Daghfous; S Kastalli; S Sraïri; Mohamed Hédi Loueslati; Chalbi Belkahia
Journal:  Tunis Med       Date:  2003-11
View more
  7 in total

Review 1.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

2.  A mouse model of severe halothane hepatitis based on human risk factors.

Authors:  Christine M Dugan; Allen E MacDonald; Robert A Roth; Patricia E Ganey
Journal:  J Pharmacol Exp Ther       Date:  2010-02-02       Impact factor: 4.030

3.  Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis.

Authors:  Christine M Dugan; Aaron M Fullerton; Robert A Roth; Patricia E Ganey
Journal:  Toxicol Sci       Date:  2011-01-18       Impact factor: 4.849

Review 4.  Perioperative Evaluation and Management of Patients With Cirrhosis: Risk Assessment, Surgical Outcomes, and Future Directions.

Authors:  Kira L Newman; Kay M Johnson; Paul B Cornia; Peter Wu; Kamal Itani; George N Ioannou
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-31       Impact factor: 11.382

5.  Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Pro™ (New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments.

Authors:  Charles M Skinner; Isabelle R Miousse; Laura E Ewing; Vijayalakshmi Sridharan; Maohua Cao; Haixia Lin; D Keith Williams; Bharathi Avula; Saqlain Haider; Amar G Chittiboyina; Ikhlas A Khan; Mahmoud A ElSohly; Marjan Boerma; Bill J Gurley; Igor Koturbash
Journal:  Food Chem Toxicol       Date:  2018-09-30       Impact factor: 6.023

6.  Ether in the developing world: rethinking an abandoned agent.

Authors:  Connie Y Chang; Elisabeth Goldstein; Nitin Agarwal; Kenneth G Swan
Journal:  BMC Anesthesiol       Date:  2015-10-16       Impact factor: 2.217

7.  Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.

Authors:  Julie Massart; Karima Begriche; Caroline Moreau; Bernard Fromenty
Journal:  J Clin Transl Res       Date:  2017-02-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.